This segment focuses on the research, development, and commercialization of innovative therapies for various types of cancer. BrightGene's R&D activities include the development of antibody-drug conjugates (ADCs) targeting solid tumors and brain metastases, as well as novel non-antibody dependent tumor targeting conjugates. The company utilizes advanced technologies such as ADC cytotoxic payloads comprising Maytansinoids, Auristatins, and Calicheamicin. This segment addresses significant unmet needs in cancer treatment, aiming to improve patient outcomes through targeted therapies. BrightGene's market positioning is strengthened by its focus on high-barrier intermediates and APIs, providing a competitive advantage in the oncology market. Future opportunities include expanding the pipeline with new drug candidates and exploring partnerships for global market access. Regulatory and clinical aspects involve rigorous clinical trials and FDA approval processes. This segment is a key area for BrightGene's growth, with potential for significant impact on cancer treatment.

This segment is dedicated to the development of treatments for type 2 diabetes and related metabolic disorders. BrightGene is actively researching and developing orally available GLP-1RA peptides, aiming to provide more convenient and effective treatment options for patients. The company's research involves the synthesis and formulation of these peptides, as well as preclinical and clinical trials to evaluate their efficacy and safety. This segment addresses the growing global prevalence of diabetes and the need for innovative therapies. BrightGene's market positioning is enhanced by its focus on high-quality APIs and formulations. Future opportunities include expanding the product portfolio with new drug candidates and exploring partnerships for global market access. Regulatory and clinical aspects involve rigorous clinical trials and regulatory approvals. This segment is crucial for BrightGene's growth, with the potential to significantly improve the lives of patients with diabetes.

This segment focuses on the research, development, and manufacturing of generic APIs (Active Pharmaceutical Ingredients) and FDFs (Finished Dosage Forms). BrightGene develops a wide range of generic drugs, including cardiovascular, antibacterial, antifungal, and iron supplement products. The company utilizes advanced chemical synthesis and formulation technologies to produce high-quality APIs and finished dosage forms. This segment addresses the need for affordable and accessible medicines, contributing to improved patient outcomes. BrightGene's market positioning is strengthened by its expertise in high-barrier intermediates and APIs, providing a competitive advantage in the generic drug market. Future opportunities include expanding the product portfolio with new generic drugs and exploring partnerships for global market access. Regulatory and clinical aspects involve rigorous testing and regulatory approvals. This segment is a core part of BrightGene's business, ensuring the availability of essential medicines.